Abstract
Increased overall survival for patients with glioma brain tumours is associated with mutations in the metabolic regulator isocitrate dehydrogenase 1 (IDH1). Gliomas develop within a mechanically challenged microenvironment that is characterized by a dense extracellular matrix (ECM) that compromises vascular integrity to induce hypoxia and activate HIF1α. We found that glioma aggression and patient prognosis correlate with HIF1α levels and the stiffness of a tenascin C (TNC)-enriched ECM. Gain- and loss-of-function xenograft manipulations demonstrated that a mutant IDH1 restricts glioma aggression by reducing HIF1α-dependent TNC expression to decrease ECM stiffness and mechanosignalling. Recurrent IDH1-mutant patient gliomas had a stiffer TNC-enriched ECM that our studies attributed to reduced miR-203 suppression of HIF1α and TNC mediated via a tension-dependent positive feedback loop. Thus, our work suggests that elevated ECM stiffness can independently foster glioblastoma aggression and contribute to glioblastoma recurrence via bypassing the protective activity of IDH1 mutational status.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Change history
04 April 2023
A Correction to this paper has been published: https://doi.org/10.1038/s41556-023-01126-8
References
Brat, D. J. et al. Comprehensive, integrative genomic analysis of diffuse lower-grade gliomas. N. Engl. J. Med. 372, 2481–2498 (2015).
Yan, H. et al. IDH1 and IDH2 mutations in gliomas. N. Engl. J. Med. 360, 765–773 (2009).
Van den Bent, M. J. et al. Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. J. Clin. Oncol. 31, 344–350 (2013).
Cairncross, G. et al. Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. J. Clin. Oncol. 31, 337–343 (2013).
Losman, J.-A. J. A. & Kaelin, W. G. What a difference a hydroxyl makes: mutant IDH, (R)-2-hydroxyglutarate, and cancer. Genes Dev. 27, 836–852 (2013).
Zhao, S. et al. Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1. Science 324, 261–265 (2009).
Koivunen, P. et al. Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation. Nature 483, 484–488 (2012).
Levental, K. R. et al. Matrix crosslinking forces tumor progression by enhancing integrin signaling. Cell 139, 891–906 (2009).
Mouw, J. K. et al. Tissue mechanics modulate microRNA-dependent PTEN expression to regulate malignant progression. Nat. Med. 20, 360–367 (2014).
Kumar, S. & Weaver, V. M. Mechanics, malignancy, and metastasis: the force journey of a tumor cell. Cancer Metastasis Rev. 28, 113–127 (2009).
Lopez, J. I., Kang, I., You, W.-K., McDonald, D. M. & Weaver, V. M. In situ force mapping of mammary gland transformation. Integr. Biol. (Camb) 3, 910–921 (2011).
Geiss, G. K. et al. Direct multiplexed measurement of gene expression with color-coded probe pairs. Nat. Biotechnol. 26, 317–325 (2008).
Colman, H. et al. A multigene predictor of outcome in glioblastoma. Neuro-Oncol. 12, 49–57 (2010).
Ruoslahti, E. Brain extracellular matrix. Glycobiology 6, 489–492 (1996).
Wade, A. et al. Proteoglycans and their roles in brain cancer. FEBS J. 280, 2399–2417 (2013).
Zimmermann, D. R. & Dours-Zimmermann, M. T. Extracellular matrix of the central nervous system: from neglect to challenge. Histochem. Cell Biol. 130, 635–653 (2008).
Cancer Genome Atlas Research NetworkComprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455, 1061–1068 (2008).
Brennan, C. W. et al. The somatic genomic landscape of glioblastoma. Cell 155, 462–477 (2013).
Masson, N. & Ratcliffe, P. J. Hypoxia signaling pathways in cancer metabolism: the importance of co-selecting interconnected physiological pathways. Cancer Metab. 2, 3 (2014).
Koperek, O., Akin, E., Asari, R., Niederle, B. & Neuhold, N. Expression of hypoxia-inducible factor 1 α in papillary thyroid carcinoma is associated with desmoplastic stromal reaction and lymph node metastasis. Virchows Arch. 463, 795–802 (2013).
Midwood, K. S. & Orend, G. The role of tenascin-C in tissue injury and tumorigenesis. J. Cell Commun. Signal. 3, 287–310 (2009).
Turcan, S. et al. IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature 483, 479–483 (2012).
Chesnelong, C. et al. Lactate dehydrogenase A silencing in IDH mutant gliomas. Neuro-Oncol. 16, 686–695 (2014).
Tarhonskaya, H. et al. Non-enzymatic chemistry enables 2-hydroxyglutarate-mediated activation of 2-oxoglutarate oxygenases. Nat. Commun. 5, 3423 (2014).
Wierenga, A. T. J., Vellenga, E. & Schuringa, J. J. Convergence of hypoxia and TGFβ pathways on cell cycle regulation in human hematopoietic stem/progenitor cells. PLoS ONE 9, e93494 (2014).
Marucci, G. et al. Pathological spectrum in recurrences of glioblastoma multiforme. Pathologica 107, 1–8 (2015).
Li, R. et al. Genetic and clinical characteristics of primary and secondary glioblastoma is associated with differential molecular subtype distribution. Oncotarget 6, 7318–7324 (2015).
Barcellos-Hoff, M. H. & Ravani, S. A. Irradiated mammary gland stroma promotes the expression of tumorigenic potential by unirradiated epithelial cells. Cancer Res. 60, 1254–1260 (2000).
Paszek, M. J. et al. Tensional homeostasis and the malignant phenotype. Cancer Cell 8, 241–254 (2005).
Miroshnikova, Y. A. et al. Engineering strategies to recapitulate epithelial morphogenesis within synthetic three-dimensional extracellular matrix with tunable mechanical properties. Phys. Biol. 8, 026013 (2011).
Chappell, W. H. et al. Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health. Oncotarget 2, 135–164 (2011).
Chang, J. H. et al. MicroRNA-203 modulates the radiation sensitivity of human malignant glioma cells. Int. J. Radiat. Oncol. Biol. Phys. 94, 412–420 (2016).
Liao, H. et al. MiR-203 downregulation is responsible for chemoresistance in human glioblastoma by promoting epithelial-mesenchymal transition via SNAI2. Oncotarget 6, 8914–8928 (2015).
Le, L. T.-N. et al. Loss of miR-203 regulates cell shape and matrix adhesion through ROBO1/Rac/FAK in response to stiffness. J. Cell Biol. 212, 707–719 (2016).
Scherr, M. et al. Lentivirus-mediated antagomir expression for specific inhibition of miRNA function. Nucleic Acids Res. 35, e149 (2007).
Williams, S. C. et al. R132H-mutation of isocitrate dehydrogenase-1 is not sufficient for HIF-1α upregulation in adult glioma. Acta Neuropathol. 121, 279–281 (2011).
Xu, W. et al. Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases. Cancer Cell 19, 17–30 (2011).
Noushmehr, H. et al. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell 17, 510–522 (2010).
Evans, S. M. et al. Hypoxia is important in the biology and aggression of human glial brain tumors. Clin. Cancer Res. 10, 8177–8184 (2004).
Vordermark, D. Significance of hypoxia in malignant glioma. Re: Evans et al. Hypoxia is important in the biology and aggression of human glial brain tumors. Clin Cancer Res 2004;10:8177–84. Clin. Cancer Res. 11, 3966–3967 (2005); Evans, S. M. et al. response 3967–3968.
Lu, K. V. et al. VEGF inhibits tumor cell invasion and mesenchymal transition through a MET/VEGFR2 complex. Cancer Cell 22, 21–35 (2012).
Johnson, K. R., Leight, J. L. & Weaver, V. M. Demystifying the effects of a three-dimensional microenvironment in tissue morphogenesis. Methods Cell Biol. 83, 547–583 (2007).
Sarkaria, J. N. et al. Use of an orthotopic xenograft model for assessing the effect of epidermal growth factor receptor amplification on glioblastoma radiation response. Clin. Cancer Res. 12, 2264–2271 (2006).
Turcan, S. et al. Efficient induction of differentiation and growth inhibition in IDH1 mutant glioma cells by the DNMT inhibitor decitabine. Oncotarget 4, 1729–1736 (2013).
Kriegel, A. J. & Liang, M. MicroRNA in situ hybridization for formalin fixed kidney tissues. J. Vis. Exp. 81, 50785 (2013).
Lakins, J. N., Chin, A. R. & Weaver, V. M. Exploring the link between human embryonic stem cell organization and fate using tension-calibrated extracellular matrix functionalized polyacrylamide gels. Methods Mol. Biol. 916, 317–350 (2012).
Acknowledgements
We thank K. Lu for the B20 mouse experiment with input from G. Bergers; C. Cowdrey and A. Shai for tissue collection support; and I. Acerbi for IRB paperwork. Animal handling and tissue preparation was supported by L. Korets and N. Korets. This work was supported by US National Institutes of Health NCI R01 grants CA138818-01A1, CA192914-01, CA174929-01, and 2R01CA085482-11A1 (V.M.W.), U54 grants CA163155-01 and CA143836-01 (V.M.W.), US National Institutes of Health NCI F31CA180422-01A1 (Y.A.M.), NSF GRFP 1144247 (Y.A.M.), US DOD BCRP grant W81XWH-07-1-0538 (J.K.M.), NINDS R01 NS081117 (J.J.P.), NINDS R21 NS088114 and NBTS (A.I.P.).
Author information
Authors and Affiliations
Contributions
V.M.W., Y.A.M. and J.K.M. conceived the project. T.R.M., K.L., J.J.P. and Y.A.M. were involved in patient recruitment and human tissue collection. J.J.P. performed human patient sample selection and performed NanoString nCounter gene expression analysis with G.F.R. Y.A.M. and J.M.B. performed mechanical testing. Y.A.M. and J.K.M. performed immunohistological analyses, imaging analyses, and quantification. J.M.B. conducted animal injections. J.M.B., Y.A.M. and J.K.M. monitored mouse colonies, and processed and analysed mouse and human tissues. J.K.M. and Y.A.M. performed all in vitro studies. J.N.L. and Y.A.M. designed and built all shRNA, microRNA and IDH1 expression constructs. M.W.P. performed the bioinformatics analysis. A.I.P. assisted Y.A.M. with primary GBM culture and manipulations. E.C.H. and Y.K. provided the TS603 and TS667 glioma cells. V.M.W., J.K.M. and Y.A.M. wrote the manuscript with input from all authors.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Integrated supplementary information
Supplementary Figure 1 Cellularity, fibrillar collagen and vascularity are independent of ECM stiffness.
(a) Scatter plots of ECM stiffness measured by AFM in a human patient sample analyzed immediately post resection from the operating room (Fresh), post snap freezing and analyzed either within 30 minutes of being thawed in a cocktail of protein inhibitors (Frozen) or treated with either PBS (PBS) or hyaluronidase (HAse) for 60 minutes (6 samples/group were tested for all groups with the exception of the “HAse 60 mins” group where 5 samples were assessed). All samples were pooled per group with 5-6 regions tested per sample (pooled group means indicated with red lines). Group means are indicated in red (6 samples/group were tested for all groups with the exception of the “HAse 60 mins” group where 5 samples were assessed). (b) Immunohistochemistry images of patient tissue immunostained for neuronal (SMI31) or astrocytic (GFAP) processes indicating a switch in the type but not density of the cellular processes in normal versus GBM brains. Scale Bar 70 μm. (c) Correlation between measured ECM stiffness and cell number in the analyzed area revealing no relationship between the two variables (linear and exponential regressions, n = 100 areas (10 patient biopsies with 10 areas/patient), insert: representative image of the AFM method for tissue analysis). Scale Bar 150 μm. (d) Second harmonic generation (SHG) image of fibrillary collagen (purple) and CD31-immunostained vasculature (red) in human GBMs (insert: composite image of SHG and CD31 in a normal human brain). Scale Bar 70 μm. (e) Immunofluorescence images of astrocytic processes (GFAP, red) and vasculature (Collagen 1, green) in human gliotic (top) and GBM (bottom) biopsies. Scale Bar 50 μm. (f) Correlation between measured ECM stiffness and percent vascularity of the tissue (percent area positive for FVIII stain) revealing no relationship between the two variables (linear and exponential regression, n = 10 patients). (g) Distribution of ECM stiffness measured by AFM in two (labeled as mGBM model 1 and mGBM model 2) mouse xenograft models of GBM (n = 4 mice/group), normal mouse brain (n = 3 mice) as well as mGBM model 2 treated with an antiangiogenic agent, avastin (labeled as mGBM model 2 + B20, n = 5 mice) revealing a slight but non-significant reduction in ECM stiffness upon B20-mediated normalization of GBM vasculature in mouse models of GBM. All samples were pooled per group with 5 regions tested per sample (pooled group means indicated with yellow lines).
Supplementary Figure 2 R132H IDH1 expression modifies TNC expression and ECM stiffness.
(a) Immunofluorescence images and quantifications of WT and R132H IDH1 patient tissues immunostained for DAPI(blue), aggrecan (green), and versican (red) (mean ± s.e.m., n = 7 mice/group, ns by unpaired 2-sided t-test). (b) Immunofluorescence images of patient tissues immunostained for the lecticans, aggrecan (green) and versican (red). (c) Immunoblot analysis confirming the R132H and WT IDH1 status in U87 GBM line. (d) Kaplan-Meier graph showing survival of xenograft mice injected orthotopically with either U87 WT IDH1 (blue, n = 7 mice) or U87 R132H IDH1 (red, n = 7 mice) human GBM cells. (e) Histogram showing the distribution of ECM stiffness measured by AFM in xenograft tumors derived from U87 WT (blue) or R132H mutant (red) IDH1 cells (n = 5 mice/group WT IDH1, n = 4 mice/group R132H IDH1, two-sided Kolmogorov-Smirnov test P = 9.7e-4). (f) Immunofluorescence images and quantification of U87 IDH1 WT and R132H mutant xenograft tumors immunostained for pMLC2 (green, top) and pFAK397 (green, bottom) with propidium iodide (PI, red) (mean ± s.e.m., n = 7 mice/group, unpaired 2-sided t-test P = 0.0007). (g) Immunofluorescence images and quantification of TNC (green) with PI (red) in xenograft tumors derived from either WT or R132H IDH1 human primary cells (mean ± s.e.m., n = 7 mice/group, unpaired 2-sided t-test P = 0.0087). (h) Immunoblot analysis confirming lentiviral shRNA construct targeting of TNC (top). Immunofluorecence images of cellular morphology (F-actin in green and DAPI in blue) of scramble shRNA and TNC shRNA cells (bottom). Scale Bar 10 μm. (i) TNC knockdown in mouse xenograft tumors by mRNA (top) and immunofluorescence (bottom) in scramble and TNC shRNA constructs (mean ± s.d., n = 5 mice/group, unpaired 2-sided t-test P = 0.014). Scale Bars 50 μm, unless otherwise indicated.
Supplementary Figure 3 HIF1α and miR-203 regulate TNC expression.
(a) Distribution of ECM stiffness measured by AFM in xenograft tumors arising from primary R132H IDH1 cells in either HIF1α-positive or-negative regions surrounding areas of necrosis (n = 4 mice, two-sided Kolmogorov-Smirnov test P = 3.7e-2). All samples were pooled per group with 5 regions tested per sample (pooled group means indicated with yellow lines). (b) Immunofluorescence images of xenograft tumors derived from cells expressing a control scramble shRNA or an shRNA for TNC shRNA immunostained for HIF1α with PI (red). (c) mRNA expression of HIF1α (left) and TNC(right) in WT IDH1 cells expressing either scramble shRNA or shRNA targeting HIF1α, represented as % of shCNL (mean ± s.e.m., n = 6/group, unpaired 2-sided test P = 0.001). (d) Quantification of HIF1α (left) and TNC(right) protein expression in IDH1 WT cells with and without hypoxia, as indicated (mean ± s.e.m., n = 6/group, one-way ANOVA with Tukey’s multiple comparisons test P = 0.0013). (e) Representative immunoblot of WT and R132H IDH1 primary GBM cells plated on laminin-coated tissue culture plates under normoxic and hypoxic (1% oxygen) conditions probed for TNC and HIF1α. (f) Immunoblot of WT IDH1 primary human GBM cells, expressing either scramble control shRNA or shRNA targeting HIF1α, plated on lamin-coated tissue culture plates under normoxic or hypoxic (1% oxygen) conditions, as indicated, and probed for TNC induction. (g) Immunofluorescence images of xenograft tumors derived from either WT or R132H IDH1 primary human GBM cells immunostained for HIF1α (green) with PI (red); asterisks indicate areas of necrosis. Scale Bars 50 μm.
Supplementary Figure 4 Endogenous and ectopic R132H IDH1 1° GBMs cannot tune HIF1α.
(a) Immunoblots and quantification of primary human glioma cells harboring an endogenous R132H IDH1 mutation (top: TS603, bottom: BT142) plated on soft (140 Pa) or stiff (>6 kPa) substrates under normoxic and hypoxic (1% oxygen) conditions and probed for HIF1α and TNC protein expressions, as well as actin (graph shows means of 2 biological replicate samples per group). (b) Immunoblots and quantification of WT IDH1 primary human glioma cells (TS667) plated on soft (140 Pa) or stiff (>6 kPa) substrates under normoxic and hypoxic (1% oxygen) conditions and probed for HIF1α and TNC protein expressions, as well as actin (graph shows means of 2 biological replicate samples per group,). (c) Immunoblot of R132H IDH1 primary human GBM cells expressing either vector control or constitutively active HIF1α (CA-HIF1α) plated on soft (140 Pa) gels under normoxic and hypoxic (1% oxygen) conditions, as indicated, and probed for HIF1α protein expression, as well as HIF1α -driven protein expressions of TNC and LOXL2.
Supplementary Figure 5 miR-203 targets the HIF1α and TNC 3’ UTRs.
(a) Diagram of miR-203 targeting seed sequences located in 3’-untranslated regions (3’ UTRs) of human HIF1α and TNC mRNAs. (b) Quantification of miR-203 expression after RNA immunoprecipitation (RIP) using AGO2 as a bait validates that antagomiR-mediated targeting of miR-203 reduces miR-203 loading into the RISC (graph shows mean of 2 IP lysates per group). (c) Immunoblots for TNC, HIF1α, LOXL2 (as HIF1α target gene) and actin from primary human GBM cells expressing R132H IDH1 (± an antagomiR control or an antagomiR targeting miR-203, ±1% hypoxia). (d) Quantification of HIF1α and TNC protein expressions in primary human GBM cells expressing R132H IDH1 (± an antagomiR control or an antagomiR targeting miR-203, ±1% hypoxia) (means ± s.e.m., n = 3 lysates/group, One-way ANOVA with Tukey’s multiple comparisons test P = 0.0011).
Supplementary Figure 6 Regional assessment of ECM stiffness and mechanosignaling.
(a) Maps of ECM stiffness are obtained using an AFM tip where a 5 μm diameter bead is attached to the end of a cantilever. The AFM tip was brought down to indent the sample, during which the motion of the z-piezo and the applied force were recorded. The ECM stiffness was computed from the displacement of the z-piezo minus the bending of the cantilever. The number of ECM stiffness measurements made was operator-determined by the x- and y-step sizes input for a 90 μm by 90 μm grid. The example shown demonstrates how step sizes of 14 (in the x- and y-directions) result in 196 independent mechanical measurements. (b) For regionally-matched correlations between ECM stiffness and mechanosignaling, patient (and xenograft) tissues were immunostained for TNC (green) and pFAK (red). Multiple specific, patient-representative regions (4-10 regions per tumor) were identified (with the x- and y-coordinates noted and images acquired) for further AFM testing in a serial section. For subsequent AFM testing, after patient (and xenograft) tumor sections were secured for testing, the identified testing region was located via x- and y-coordinates using the optical microscope. (c) Left: Immunohistochemistry images of patient tumors immunostained for TNC (green) and pFAK (red) with DAPI (blue) with regions for AFM analysis in serial sections denoted by white boxes. Graphs illustrate individual patient correlations between TNC and pFAK. Right: AFM maps of patient tumors. Graphs illustrate individual patient correlations between elastic modulus (stiffness) and pFAK. (d) The data underlying (c left) was combined into graphs depicting regional matching of ECM stiffness and pFAK (left) and TNC and pFAK (right) to illustrate not only the correlations between the variables, but also the variability between patients within the cohort (n = 3 patient samples/group, One-way ANOVA with Tukey’s comparison P = 0.0011). (e) The data underlying (c right) was combined into a graph depicting both the patient-specific trends in elastic modulus (stiffness) and the patient variability within the cohort (n = 10 patients, 4 regions/patient sample, linear regression analysis yielding p < 0.0001 for both plots with R2 = 0.4812 for pFAK:stiffness data and R2 = 0.5850 for pFAK:TNC data). Scale Bars 200 μm (left panels) and 20 μm (right panels), as indicated.
Supplementary information
Supplementary Information
Supplementary Information (PDF 902 kb)
Rights and permissions
About this article
Cite this article
Miroshnikova, Y., Mouw, J., Barnes, J. et al. Tissue mechanics promote IDH1-dependent HIF1α–tenascin C feedback to regulate glioblastoma aggression. Nat Cell Biol 18, 1336–1345 (2016). https://doi.org/10.1038/ncb3429
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/ncb3429
This article is cited by
-
Extracellular matrix stiffness mediates uterine repair via the Rap1a/ARHGAP35/RhoA/F-actin/YAP axis
Cell Communication and Signaling (2023)
-
Cell–extracellular matrix mechanotransduction in 3D
Nature Reviews Molecular Cell Biology (2023)
-
CEBPD is a master transcriptional factor for hypoxia regulated proteins in glioblastoma and augments hypoxia induced invasion through extracellular matrix-integrin mediated EGFR/PI3K pathway
Cell Death & Disease (2023)
-
A cell cycle centric view of tumour dormancy
British Journal of Cancer (2023)
-
Schnurri-3 drives tumor growth and invasion in cancer cells expressing interleukin-13 receptor alpha 2
Cell Death & Disease (2023)